Mexico Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program, cancer research, and the lack of coronavirus expertise in Mexico. Zero tolerance for corruption: the Mexican pharma sector must…
Talent Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have moved on to new roles in their ever-expanding careers. LATAM Expertise Pedro Galvis Mexico is an interesting mix…
Mexico Mexico’s pharma market has seen steady growth in the past decade and is projected to reach over USD 13 billion by 2028. Made with Visme Presentation Maker
Mexico The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for pharmaceuticals and medical devices. Mexico remained on USTR’s Watch List in 2019 because there has not been a significant change…
Pharma Legal Handbook Cannabinoid drugs, medicinal cannabis and opioid drugs in Mexico – a comprehensive legal overview. Prepared in association with Olivares, a leading global law firm, this is an extract from The Pharma Legal Handbook: Mexico, available to purchase here for GBP 99. Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized in your…
Opinion What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office of global management consultants Korn Ferry explain what they look for when hiring Mexico GMs, and outline some of the…
Mexico Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three key reasons why fighting corrupt practices is so important. The pharmaceutical industry must act according to value-based codes, building…
Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve unemployment rates in Mexico and how the pharmaceutical industry is getting involved. The investment in human capital is an…
Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. In this article, Thompson outlines the country’s challenges to the healthcare system and the pharma…
Mexico David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies. In Mexico, approximately 15 percent of patients treated with therapies for rare diseases, dismiss the concept of adherence to treatments. In Latin American Countries such as Mexico, keeping…
Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here Thompson discusses the need for stronger public-private sector alliances in the push towards universal…
Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here Cristobal discusses Mexico’s regulatory landscape and the countries advances in healthcare. Mexico has…
See our Cookie Privacy Policy Here